THERAPIX BIOSCIENCES LTD has a total of 27 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, environmental technology and biotechnology are NELSON PETER JON, BIRDIE BIOPHARMACEUTICALS INC and KALEYDE PHARMACEUTICALS AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | Canada | 4 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | China | 3 | |
#6 | Australia | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Environmental technology | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Shmulewitz Ascher | 22 |
#2 | Brener Ephraim | 22 |
#3 | Haber Elran | 21 |
#4 | Zuloff-Shani Adi | 7 |
#5 | Dotan Shahar | 5 |
#6 | Ellis Ronald | 5 |
#7 | Jones Timothy David | 4 |
#8 | Samira Sarit | 4 |
#9 | Tal Michael | 4 |
#10 | Rachamim Nurit | 4 |
Publication | Filing date | Title |
---|---|---|
WO2019145783A1 | Compositions and methods for treating obstructive sleep apnea | |
CA3068806A1 | Compositions and methods of potentiating antimicrobials | |
EP3297622A1 | Combinations of opioids and n-acylethanolamines | |
CN107530317A | The combination of Cannabinoids and N acyl ethanol amines | |
EP2892924A1 | Humanized antibodies to cluster of differentiation 3 (cd3) | |
US2015132289A1 | Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy |